US court dismisses lawsuit against Emcure over Covid-19 vaccine

When contacted a company spokesperson said, The ruling vindicates our stand.Emcure had contended in the court that the lawsuit was illegitimate and brought by HDT to compensate for its business shortcomings.HDT Bio had alleged that the Pune-based firm had stolen its vaccine technology which it had licensed to Gennova for manufacture and distribution in India.

A US Court has dismissed a lawsuit filed by HDT Bio Corp against Pune-based Emcure Pharmaceuticals.

A Federal court in Seattle, Washington, has dismissed the lawsuit lawsuit filed by HDT against Gennova Biopharmaceuticals, a unit of Emcure, regarding Covid-19 vaccine technology. HDT had named Emcure as a party in the suit, alleging non-payment of royalties and demanded a compensation of at least USD 950 million. When contacted a company spokesperson said, ''The ruling vindicates our stand''.

Emcure had contended in the court that the lawsuit was illegitimate and brought by HDT to compensate for its business shortcomings.

HDT Bio had alleged that the Pune-based firm had stolen its vaccine technology which it had licensed to Gennova for manufacture and distribution in India.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)